BioSpace News Archive

The Directors of Biotron Limited (ASX: BIT) are pleased to provide an update on the progress of the company’s proof-of-concept HIV-1 clinical trial.

- MDxHealth SA (Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the “Belgian Transparency Act”).

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase II clinical trial intended to support the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

Vienna-based company Marinomed Biotech AG (Marinomed) today announced it had secured EU-wide certification for a new product: a nasal spray that allows the decongestion of the nasal cavity without employing a pharmaceutical ingredient and tackles viral infections of the airways at the same time.

XcellBio, a proprietary provider of primary cell control technologies for immunotherapeutic solutions today announced a collaboration with Carolina BioOncology Institute (CBI) to further pre-clinical development of true personalized medicine therapies.

Rising companies in diagnostic space form strategic partnership

Savaria Corporation discloses results for its second quarter ended June 30, 2018.

Adverum Biotechnologies, Inc. reported financial results for the second quarter ended June 30, 2018 and provided a corporate update.

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A

Novavax Delivers on Key Milestones Supporting its 2018 Objectives